Total Funding
27
Total FundingPost-IPO Equity raised
Growth Score in past quarter
pts
Heat Score 27 in past quarter
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
231095
Genkyotex develops innovative drugs to block the NOX enzymes that produce oxygen radicals.
- Freddy Heitz: Head of Screening and Biotechnology
- Elias Papatheodorou: Chief Executive Officer
About the Company
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.
Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.